Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Shibeshih Belachew, Robert Hyde, Freek Verheul, Alessandra Lugaresi, Eva Havrdová, Dana Horáková, Pierre Grammond, Pierre Duquette, Alexandre Prat, Gerardo Iuliano, Murat Terzi, Guillermo Izquierdo, Raymond M M Hupperts, Cavit BozEugenio Pucci, Giorgio Giuliani, Patrizia Sola, Daniele L A Spitaleri, Jeannette Lechner-Scott, Roberto Bergamaschi, François Grand'Maison, Franco Granella, Ludwig Kappos, Maria Trojano, Helmut Butzkueven

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS'. Together they form a unique fingerprint.

Medicine & Life Sciences